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1. INTRODUCTION AND LITERATURE REVIEW 
 
With the increasing use of Highly Active Antiretroviral Treatment (HAART), renal disease is becoming 
an increasingly important consideration in the course of the disease. According to UNAIDS estimates, 
35 million people were living with HIV at the end of 2012. Sub-Saharan Africa bears the largest 
burden of the disease with 25 million people (approximately 69%) living with the disease. The 
number of children and adults in sub-Saharan Africa receiving antiretroviral therapy (ART) is steadily 
increasing, with 56% of those eligible now receiving treatment. With scaling up of treatment in 
recent years, AIDS-related deaths have decreased by 24% compared to 2005.1 Changes in the WHO 
guidelines for eligibility for antiretroviral therapy (ART), including CD4 counts of below 350 cell/µL, 
will result in a larger number of people living with HIV/AIDS and the complications thereof.2 In 
resource-limited settings like sub-Saharan Africa, predictors of outcome are becoming increasingly 
important in the decision to initiate HAART. Renal disease is an independent risk factor for 
progression to AIDS and overall mortality. 
 
1.1 Prevalence of Chronic Kidney Disease in HIV infection 
The worldwide prevalence of chronic kidney disease (CKD) in HIV patients has been difficult to 
ascertain due to a paucity of data, especially from developing countries. A cross-sectional study done 
across 33 countries in Europe revealed that the prevalence of CKD using the Cockcroft-Gault formula 
to estimate glomerular filtration rate (eGFR) was 3.5% and that of the Modification of Diet in Renal 
Disease(MDRD) formula was 4.7%.3 Kidney disease was defined as the presence of albuminuria 
and/or low GFR, based on serum creatinine measurements. In sub-Saharan Africa prevalence rates 
range between 6% and 45%.4 Varying degrees of prevalence have been found in studies done across 
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Africa. In a study done in Zambia of 25 779 patients started on ART, 33.5% were found to have renal 
insufficiency (measured by serum creatinine at baseline). Risk of mortality was also shown to be 
elevated at or before 90 days.5 A Nigerian study revealed a 38% prevalence of renal disease in HIV 
positive patients.6 A Rwandan study showed a lower prevalence with 2.4% of patients with a low 
eGFR and 8.7% with proteinuria.7 A study performed in Malawi revealed a high prevalence of renal 
impairment in patients with WHO early clinical staging of HIV (stages I and II), measured by 
proteinuria (23.3%) and abnormal serum creatinine (57.4%).8   In a study in Johannesburg on the 
incidence of urinary abnormalities on dipstick testing in ART-naïve patients, 30% had leucocyturia, 
33% had microscopic haematuria and 44% had microalbuminuria/ proteinuria.9  These studies 
suggest that the prevalence of kidney disease is high and point to the importance of screening for 
chronic kidney disease in all HIV-positive patients.  
 
In a study conducted at Chris Hani Baragwanath hospital in Johannesburg, 99 ART-naïve in-patients 
were biopsied and 27% revealed HIV-associated nephropathy (HIVAN), 21% HIV-associated immune 
complex disease (HIV-ICD) and 13% membranous nephropathy. The rest had features of 
nonglomerulonephritic renal disease, post infectious or mesangioproliferative glomerulonephritis 
and IgA nephropathy.10 In a study done at King Edward VII Hospital in Durban with 615 HIV positive 
ART-naïve outpatients, 6% had persistent proteinuria; 37 of these patients with persistent 
proteinuria were biopsied, 30 were found to have histology in keeping with HIVAN (83.3%). Other 
conditions detected were HIVAN combined with membranous glomerulonephritis, membranous 
glomerulonephritis and interstitial nephritis.11  Differences in results could be attributed to the high 
degree of genetic variability among black South Africans and patient selection.12 A study performed 
in the United States with 89 patients who were biopsied showed that 42 had HIVAN, 13 immune 
complex glomerulonephritis, 8 with membranous glomerulopathy, 6 with diabetic nephropathy, 5 
with membranoproliferative glomerulonephritis. The remainder showed interstitial nephritis, 
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amyloid, focal segmental glomerulosclerosis, minimal change disease, IgA nephropathy and chronic 
pyelonephritis. In this study, patients with renal disease other than HIVAN did not seem to benefit 
from the use of ARTs and viral suppression and additional therapeutic strategies were needed.13 A 
study from Groote Schuur hospital in Cape Town showed that those with HIVAN as well as immune 
complex glomerulonephritis improved with therapy. The study also highlighted various subtypes of 
HIVAN, different histological associations and their differing responses to HAART.14 These studies 
show the wide range of histological results in patients with clinical renal disease and the differing 
responses seen to treatment. This suggests that renal histology will improve management of HIV 
patients with renal disease.   
 
1.2 Risk factors for developing HIV-associated kidney disease 
Several studies have pointed to HIV infection being an independent risk factor for microalbuminuria. 
A study done in the United States showed 11% of HIV positive patients had microalbuminuria. It was 
found that the odds were 5 times higher for those with HIV to have microalbuminuria than control 
patients. Predictors for albuminuria in HIV patients included lower CD4 count, higher viral load and 
African-American race.15 In another study, older age, black race, hepatitis C infection and lower CD4 
count were independently associated with chronic kidney disease. Of note virological suppression 
was also more common with renal impairment, most likely due to higher blood levels of renally 
eliminated ARTs.16 
 
HIVAN was described as a disease entity over 20 years ago, found predominantly in the African-
American population in the United States. It is currently the third leading cause of end-stage renal 
failure in this group between the ages of 20-64.17 An association has been shown between the 
APOL1 gene on chromosome 22 (seen in African Americans) and FSGS and hypertension-attributed 
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end-stage kidney disease. It is thought this gene in Africa contributed as a survival factor to those 
infected with Trypanosoma brucei rhodesiense.18 A subsequent study revealed 17 fold higher odds 
for FSGS and 29-fold higher risk for HIVAN in those with the APOL1 variant. Untreated HIV positive 
patients with the APOL1 risk allele have a 50% risk for developing HIVAN.19 Genetic variations at the 
MYH9 locus had previously been reported to be associated with increased risk of FSGS in the African 
American population.20 Additional risk factors for HIVAN includes low CD4 count (<200 cells/µL), high 
HIV viral load (>4000 copies/mL) and family history of renal disease.16 
Other risk factors for the development of proteinuric kidney disease in this subset of patients 
includes co-morbid diseases such as diabetes mellitus and hypertension. They increase the risk for 
CKD 10-fold and are becoming increasingly common in HIV infected individuals.  In the Multicentre 
AIDS Cohort Study the prevalence of diabetes mellitus was 14%, which was 4 times higher than that 
of the seronegative control group. It was found to be linked to cumulative exposure to nucleoside 
reverse-transcriptase inhibitors, which are part of first line regimens for ART and are commonly 
included in most regimens given to patients. In the same study, the prevalence of hypertension was 
3 times higher than in the control group. These results point to the importance of optimizing blood 
pressure and glycaemic control in order to minimize the impact of CKD concomitant with HIV 
infection.  
 
1.3 Pathogenic effects of Viral Infection on the Kidney  
1.3.1 HIV Virus Infection of Renal Cells  
The question of whether HIV directly infects renal cells is an issue central to pathogenesis. CD4 and 
chemokine receptors which are needed for viral entry are not typically expressed on these cells 
therefore viral replication is likely restricted. Viral products are produced by renal epithelial cells 
when viral constructs are transfected. Cell expression of CXCR4 and CD4 chemokine receptors allow 
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viral replication. It is still unclear how HIV-1 enters renal cells.23 Genetic variability of gp120 seems to 
influence renal infectivity. Lymphocytes possibly permit cell infection in a monolayer via transcytosis.  
Another possible mechanism is transfer of CCR5 between cells (these have cytoplasmic and cell 
surface components of the original cell), thus allowing entry of the HIV virus into renal cells without 
endogenous expression of the co-receptor. Dendritic cells have been found to play a part in binding, 
dissemination and transfer of the virus in different tissues and may also play a role in infection of 
renal cells. DEC-205 (the dendritic cell C-type lectin receptor) has been found to assist entry of the 
virus into renal tubular cells. Therefore there is increasing evidence to suggest that renal cells may 
support viral replication.24 
1.3.2 Viral proteins 
Studies in transgenic mice expressing viral proteins have suggested that vpr and macrophage-specific 
expression of HIV proteins may play a role in the evolution of FSGS. Some suggest that nef may 
affect the severity of interstitial nephritis, but not the glomerular changes seen in HIVAN.25 
Podocyte-restricted expressions of vif, nef, tat, vpr and rev have been shown to induce many of the 
features of HIVAN in mice models.26 In HIVAN specimens, apoptosis of renal epithelial cells mediated 
by caspase activation and Fas up-regulation has been seen.23 
1.3.3 Changes in Renal Microvasculature 
A recognized feature of HIV infection includes deposition of platelets and thrombi in the vessel wall 
and endothelial dysfunction caused by abnormalities of the clotting cascade. How HIV affects renal 
vasculature is important in understanding the pathogenesis of thrombotic microangiopathy (TMA) 
and other HIV-associated renal diseases. Expression of TNF and interleukin-1 is up-regulated in HIV 
infection of the kidney. This further drives renal inflammation and can contribute to changes in 
regulation of the clotting cascade. Fas-mediated apoptosis of endothelial cells is triggered by HIV 
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proteins. Down-regulation of von Willebrand factor is a primary component of TMA by antibodies 
against the ADAMTS13 protease.27 
1.3.4 Host Factors 
As mentioned before, genetic variations such as the APOL1 and MYH9 variants have been found to 
have a strong association with HIV kidney disease in African-Americans. 
It has been suggested that through activation of cytokine pathways disease phenotype could affect 
the host response to viral infection. It has been shown that up-regulation of many genes which 
mediate the inflammatory response in renal epithelial cells such as chemokines, cytokines and 
adhesion molecules   occur in patients with HIV-associated renal disease. A number of such up-
regulated genes are targets of NF-B and IL-6. TNF and IL-6 expression by tubular and mesangial 
epithelial cells increase HIV-1 expression by entering monocytes and further driving cytokine 
production. The part played by inflammatory mediators in the pathogenesis of HIVAN is not yet 
entirely understood.28 
Chronic HIV infection is associated with high levels of immunoglubulins. It is suggested that immune 
complexes circulating in the systemic circulation are deposited in the microvasculature of the kidney, 
leading to HIV immune complex kidney diseases.29 
 
1.4 Detection of renal disease 
1.4.1 Renal function 
Renal function is determined using various methods. In patients with lower relative muscle mass 
(e.g., older patients, women, and patients with low body weight due to cachexia or chronic illness), 
abnormal renal function may not be recognized with serum creatinine alone. eGFR is commonly 
used and is more accurate. The GFR is defined as the volume of fluid filtered from the glomerular 
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capillaries into Bowman’s capsule per unit time. A number of formulae have been devised to 
estimate GFR based on serum creatinine levels and other parameters such as age, race, gender and 
weight. A widely used formula is the Cockcroft-Gault formula, which incorporates age, gender, mass 
and serum creatinine. A more recently advocated formula is the MDRD formula. This uses the four 
variables of race, gender, age and serum creatinine. Both formulae have a level of bias and tend to 
overestimate the GFR. Another recently devised formula is the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula which takes into account race, age, gender and serum creatinine. 
None of the above formulae have been validated for HIV patients. The one that is used more 
prevalently is the simplified MDRD equation.  
1.4.2 Proteinuria 
Another marker used to screen for CKD is the level of protein in the urine. Persistent proteinuria of 
more than 30mg albumin per gram of creatinine in the urine is indicative of CKD. Microalbuminuria 
is a level of 30-299 mg/g albumin in the urine which is usually not detected by urine dipstick 
methods. It is associated with abnormal glycosylation in diabetes or systemic processes in other 
chronic diseases and is a marker of early vessel damage. In HIV positive patients, proteinuria has 
been associated with a higher risk of CKD, ESRD, AIDS-defining illness and mortality. This relationship 
seen between proteinuria and these outcomes implies that it may be a sign of diffuse vascular 
processes which have an effect both within and outside the kidney.15 
1.4.3 AKI and CKD 
A vital step in evaluating kidney disease is the differentiation between acute kidney injury (AKI) and 
CKD.  AKI is defined as a clinical syndrome with an abrupt deterioration in GFR over days to weeks. 
The Acute Kidney Injury Network (AKIN) defines AKI as “an abrupt (within 48 hours) reduction in 
kidney function currently defined as an absolute increase in serum creatinine of more than or equal 
to 0.3mg/dL (≥26.4 μmol/l), a percentage increase in serum creatinine of more than or equal to 50% 
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(1.5-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5ml/kg 
per hour for more than six hours).”21 
 Chronic kidney disease has been defined as evidence of kidney damage that persists for 3 months or 
more.22 The stages of chronic kidney disease are shown in the table below. 
Table 1. Stages of chronic kidney disease 
Stage Description GFR, mL/min per 1.73m² 
I Kidney damage with normal or increased GFR ≥90 
II Kidney damage with mildly decreased GFR 60-89 
III Moderately decreased GFR 30-59 
IV Severely decreased GFR 15-29 
V Kidney failure <15 (or dialysis) 
 
Note: Reproduced with the kind permission of the National Kidney Foundation. Adapted from 
K/DOQ I clinical practice guidelines for chronic kidney disease: evaluation, classification, and 
stratification. Am J Kidney Dis 2002, 39:1-266 
 
As seen in the table, estimates of GFR using the C-G or MDRD equation are used to grade renal 
function. ESRD is defined as stage V CKD. To screen for early CKD, guidelines mention the 
importance of measuring “spot” urinary albumin and/or protein to creatinine ratios.  
Acid-base and electrolyte disturbances are commonly found in HIV positive hospitalized patients, 
many of which are drug-induced.12 
9 
 
 
1.5 Clinical Spectrum of HIV-related Kidney Disease 
Table 2 below shows a summary of the clinical syndromes of HIV-related kidney disease and their 
causes. 
Table 2. Clinical syndromes of HIV-related kidney disease  
Clinical syndrome Features Clinical 
assessment 
Specific causes 
Glomerular syndrome Nephrotic syndrome: 
proteinuria + 
haematuria ± 
hypertension 
 
First: viral-related 
diseases 
Then, drug-related 
diseases 
HIVAN in blacks; MPGN in whites; 
HIVICK; lupus-like nephropathy; 
HBV, HCV coinfection; 
PIGN 
Foscarnet; interferon; enfurtide 
Tubular syndrome Acute kidney injury, 
Fanconi syndrome 
(proximal tubular injury), 
diabetes insipidus, 
crystal nephropathy 
Drug-related diseases Aminoglycosides; foscarnet; 
tenofovir; cidovofir; amphotericin; 
indinavir; ciprofloxacin; intravenous 
acyclovir 
Interstitial nephropathy Tubular proteinuria, ± 
haematuria 
First: drug 
nephrotoxicity 
 
Then HIV-related 
diseases 
Indinavir; cidofovir; atazanavir; 
aciclovir; foscarnet; interferon; 
abacavir 
HIV-associated interstitial 
infiltrates; sarcoıdosis, Sjögren 
syndrome; opportunistic infection; 
IRIS; DILS 
Vascular nephropathy Hypertension ± low-
range proteinuria, ± 
mechanic haemolytic 
anaemia 
First: HIV-related 
diseases 
Then: drug 
nephrotoxicity 
HIV-associated TMA; APLS 
Valaciclovir; interferon 
 
Note: Adapted from Kopp J, Fabian J, Naicker S. HIV and the Kidney. In Clinical Comprehensive 
Nephrology 4th edition p 675-686, with permission from Elsevier. 
10 
 
APLS = Antiphospholipid syndrome; DILS = Diffuse Infiltrative Lymphocytosis Syndrome; HBV = 
Hepatitis B virus; Hepatitis C virus; IRIS = Immune Reconstitution Syndrome; MPGN = 
Membranoproliferative glomerulonephritis; PIGN = Post-infectious glomerulonephritis      
1.5.1 Acute Kidney Injury 
AKI is common in individuals with HIV infection and is linked to increased morbidity and mortality. 
The risk of in-patient mortality is six-fold higher in ART-naive patients with AKI.12 Risk factors include 
severe immunosuppression (CD4 count < 200cells/ µL), older age, serious systemic illness or 
infection, exposure to nephrotoxic agents and pre-existing CKD.  Common causes of AKI in this group 
of patients are sepsis, AKI from drug toxicity associated with treatment of opportunistic infections, 
herbal ingestion, gastroenteritis with dehydration and TMA.4,12 Nephrotoxicity related to ART is 
another cause of AKI, although its incidence is relatively low. The commonest effects are crystal-
induced obstruction secondary to protease inhibitors and proximal tubule damage related to 
tenofovir.  Early recognition of proximal tubule injury in tenofovir-related AKI is important to prevent 
irreversible chronic tubulointerstitial fibrosis.30 Awareness of possible underlying CKD in patients 
admitted to hospital with AKI is an important consideration for clinicians treating these patients.12 In 
a study of patients admitted with AKI to Charlotte Maxeke Johannesburg Academic Hospital 
(CMJAH), the outcomes for HIV positive and negative patients were similar when given appropriate 
therapy (including dialysis).31 
1.5.2 Chronic Kidney Disease 
HIV affects the kidney in a number of ways. It can affect either a single or multiple compartments 
and the effects are highly variable. The importance of initiation of HAART in HIV related kidney 
disease has been stressed, as these patients are at increased risk of rapid deterioration of renal 
function to ESRD. Even with HAART, CKD is associated with an increased progression to AIDS and 
death. Anaemia is more severe in HIV-associated ESRD and these patients are at increased risk of 
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renal osteodystrophy. Dyslipidaemia associated with HAART and proteinuric renal disease leads to a 
higher risk of cardiovascular disease. Studies have reported an increased association between 
microalbuminuria and cardiovascular risk factors (increased systolic blood pressure and glucose 
resistance).15 
Many patients with HIV-associated kidney disease present with renal dysfunction and proteinuria/ 
nephrotic syndrome. The only reliable way to determine the cause is by histological diagnosis.  
HIVAN has been classified by the WHO as an AIDS-defining illness and therefore the initiation of ART 
is mandatory irrespective of the CD 4 count. There have been studies which suggest that other HIV-
associated kidney diseases do not respond to the same degree to ARTs.13 Other reports have shown 
that some non-HIVAN lesions do respond well to therapy.14, 32 It was also seen that certain 
histological subtypes of HIVAN respond poorly to HAART.14 This highlights the importance of 
histological diagnosis in this group of patients, as it has an impact on the outcome of patients.  
 
1.5.2.1 HIV-associated Nephropathy 
HIVAN is 7-10 times more common in men than woman and is found predominantly in people of 
African descent. With the introduction of HAART, there has been a decline in deaths from AIDS and 
the number of black patients living with HIV has markedly increased.  Subsequently it is to be 
expected that the incidence of ESRD secondary to HIVAN will rise as it is this patient demographic 
which is at risk.  Most patients in our setting in sub-Saharan Africa present late with advanced CKD. 
The delay in detection of HIVAN could be due to a lack of routine initial screening for proteinuria and 
renal dysfunction.33, 34 Another reason is the relative absence of overt signs such as peripheral 
oedema and hypertension. The only definitive way to establish the diagnosis of HIVAN is by renal 
biopsy. It has been recommended that renal biopsy be offered to patients with unexplained renal 
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abnormalities (i.e. kidney failure and/or significant proteinuria and/or microscopic haematuria) as 
the treatment implications and prognosis are influenced by the biopsy results.13 
 
Clinical presentation HIVAN is a form of glomerular disease characterized by proteinuria/nephrotic 
syndrome, focal segmental glomerulosclerosis with collapse of the glomerular tuft and a rapid 
progression to ESRD within 6-12 months if not treated. Classically the clinical manifestation is that of 
nephrotic syndrome without peripheral oedema despite severe hypoalbuminaemia. Patients are 
generally normotensive even though renal insufficiency is present and tend to have hyponatraemia; 
hence it is thought to be a “salt wasting disease”.35 On ultrasonography they have normal to large 
size kidneys which are highly echogenic. The study done in Cape Town revealed the clinical 
correlations of nephrotic range proteinuria, systolic blood pressure <140 and diastolic blood 
pressure <90, kidney size of 12cm on ultrasound with no peripheral oedema to be 91.3% specific for 
HIVAN but 15.6% sensitive.14 
Pathology findings “HIVAN is characterized by a constellation of pathologic ﬁndings involving 
glomerular, tubular, and interstitial compartments. Glomerular pathologic ﬁndings include focal 
glomerulosclerosis, with prominent collapse of the glomerular tuft. Tubular disease is characterized 
by the development of tubular dilatation, accompanied by atrophy and ﬂattening of tubular 
epithelial cells. There is also prominent lymphocytic inﬁltration of the interstitium.”35 Tubuloreticular 
inclusions are also commonly found.38  
 
 
13 
 
 
 
 
Figure 1 Histological features of HIVAN  
Reproduced from http://emedicine.medscape.com/article/246031-overview with kind permission 
from Moro O Salifu, MD, MPH, FACP, State University of New York Downstate Medical Center. 
Accessed on 19 November 2013. 
 
Light microscopy with trichrome staining 
showing the collapse of the glomerular tuft, 
with segmental glomerular and interstitial 
sclerosis (bluish staining). The renal tubules 
are dilated and filled with proteinaceous 
material. 
Light microscopy showing prominent 
microcystic dilatation of renal tubules filled 
with proteinaceous material; this finding is 
characteristic of human immunodeficiency 
virus (HIV)–associated nephropathy, 
although it may also be observed in chronic 
glomerulonephritis 
 
chronic glomerulonephritis. 
Electron microscopy showing a segment of 
the glomerular basement membrane; foot 
process effacement (black arrow) and 
prominent tubuloreticular inclusions (red 
arrow) are present. 
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Treatment of HIV HIV infection itself appears to be a cause of HIVAN; therefore ART is a logical 
choice for first-line therapy. HIVAN has been classified by the WHO as an AIDS-defining condition 
and therefore ARTs should be initiated regardless of CD4 count.37 HAART seems to be more effective 
than monotherapy. A study done on patients with biopsy-proven HIVAN showed that those who 
received therapy had better renal survival compared to those who did not receive therapy.38 
Another study from the US showed slower progression to ESRD with those who received HAART.13 
HAART has also been thought to decrease the incidence of de novo HIVAN. Angiotensin Converting 
Enzyme Inhibitors (ACE-Is) have been shown in a series of studies to slow the progression to renal 
failure of proteinuric renal diseases. A study was done on 44 patients with HIVAN on histology and 
early renal disease who were given the choice of fosinopril. In those who consented, serum 
creatinine remained stable in the majority of patients. One of the 28 progressed to ESRD after a 
median follow up of 479.5 days. All those who declined fosinopril progressed to ESRD after a mean 
of 146 days.39 Another study showed a delay in progression of renal failure in a retrospective cohort 
of 18 patients with HIVAN.40 Current guidelines suggest the initiation of ACE-Is as first line therapy in 
those with hypertension and proteinuria. A number of studies reported a significant improvement in 
proteinuria and renal function for HIVAN patients on corticosteroid therapy in the time prior to 
HAART therapy. Another retrospective study showed an improvement in creatinine clearance over 
time (+3.32 mL/min), compared with a deterioration (-5.57mL/min) in non-corticosteroid treated 
patients.41 Strong evidence supporting the use of prednisone therapy in HIVAN came from a 
prospective study of 20 patients. They were treated with high dose prednisone (60mg/day) for 2-11 
weeks, and then a tapering period of 2-26 weeks. The majority of patients experienced significant 
improvement in proteinuria and renal function. A number of patients relapsed after therapy was 
stopped, but improved after re-initiation of treatment.42 Owing to the small sizes of the studies, 
short follow up periods and lack of randomization, there is difficulty in drawing conclusions 
regarding their use in HIVAN. It has been recommended by the Infectious Disease Society of America 
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guidelines that patients whose kidney function deteriorates despite HAART, who have no evidence 
of active infection, could be considered for a short course of corticosteroid therapy.33 
 
Prognosis Diagnosis of HIVAN is generally late in the course of disease in most patients and many 
have advanced renal failure on diagnosis. Without treatment, most develop ESRD1-4 months after 
the diagnosis is made. Clinical manifestations linked to a higher risk of progressive renal failure is 
seen in patients with increased proteinuria, elevated serum creatinine level, decreased CD4 count, 
higher viral load and prior to HAART. Histological features of progression to ESRD and a poor 
response to ART are a high index of chronic damage with a high percentage of sclerotic glomeruli 
and chronic damage score >75.43,44 As discussed above, treatment with a variety of agents has been 
found to prolong renal survival. Compared to other patients with ESRD, patients with HIVAN have 
decreased survival. In a study done on patients requiring chronic renal replacement therapy, those 
with HIVAN had a 4.74 fold higher risk of mortality when compared to other patients with ESRD from 
other causes.45 
1.5.2.2 HIV Immune Complex Disease 
HIV-ICD is an immune complex-mediated form of glomerulonephritis, and is the second most 
common diagnosis obtained from biopsies of patients with CKD. The  study mentioned previously 
done in Johannesburg found that of the 99 HIV patients with renal insufficiency biopsied, 21% had 
HIV-ICD (the largest group was HIVAN at 27%).10 Another South African study of 221 patients 
biopsied in Cape Town showed that 42 had features of both HIVAN and HIV-ICD and 16 had features 
of HIV-ICD alone.14  While HIVAN has a strong predilection for black patients, in contrast immune 
complex glomerulonephritis has been reported mainly in white and Asian patients, although they 
may also occur in black patients.10,14 The clinical profile of the patients was similar to that of HIVAN, 
although they had less proteinuria and a better serum creatinine and albumin on average.10 
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HIV-ICD presents with a variety of histological changes. The renal infiltrate consists primarily of B 
lymphocytes, in contrast to HIVAN where it is composed mainly of T lymphocytes and 
macrophages.46 The pathogenesis is thought to be associated with the development of polyclonal 
hypergammaglobulinaemia, thus promoting the circulation of immune complexes which are then 
passively trapped in the kidney. Activation of inflammatory mediators subsequently occurs which 
results in secondary renal damage similar to that of lupus nephritis. Another effect is thought to be 
the in-situ deposition of antibodies binding to HIV viral antigens within the kidney.46 “In the HIVICK 
group, the predominant histologic pattern included variable mesangial alterations, with identifiable 
immune deposits within the mesangial and paramesangial regions. In addition, some of the biopsies 
showed a peculiar and to our knowledge not previously described pattern, in which a varying number 
of subepithelial immune deposits were seen inducing a peculiar localized 'ball-in-cup' reaction 
pattern from the basement membrane.” 10 
There have been conflicting reports on the benefit of HAART in patients with HIV-ICD. A study done 
by Szczech et al found that renal function in patients with lesions other than HIVAN, including 
immune complex kidney disease did not benefit from ARTs.13 Two studies in South Africa showed 
improvement in renal function with HAART irrespective of renal histology.14, 32 Immunosuppressive 
therapies, such as corticosteroids, to dampen the inflammatory response to these complexes at the 
level of the kidney have been suggested as possible additional strategies for treatment.46 
1.5.2.3 Ig A Nephropathy 
This is one of the immune-mediated renal diseases seen in HIV positive patients. It is thought to be 
as a result of immune complexes which contain HIV antigens. It is generally less severe than HIVAN 
and other variants of HIV-ICD and presents with proteinuria, haematuria and renal dysfunction. One 
small study done in Canada however, found that IgA nephropathy caused severe renal impairment 
and heavy proteinuria.47 The pathology shows diffuse or segmental mesangial matrix expansion with 
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proliferative changes. Immunofluorescence demonstrates staining primarily for IgA. Increased serum 
IgA, detectable serum IgA immune complexes and rheumatoid factor could be seen.  
1.5.2.4 Other Glomerulonephritides 
Other immune-mediated diseases have been found in HIV positive patients including membranous 
nephropathy, membranoproliferative glomerulonephritis and post-infectious glomerulonephritis. 
These are often associated with co-infection with Hepatitis B and/or C viral infection. In the study by 
Gerntholtz et al, of the 99 patients who were biopsied 13% had membranous nephropathy, 8% post-
infectious glomerulonephritis (GN) and 6% membranoproliferative GN.  It is not known if the 
pathogenesis of these is directly related to HIV infection. Explanations could include abnormal 
immune responses associated with viral infection, or responses secondary to superinfections.10 
1.5.2.5 HIV Thrombotic Microangiopathy 
HIV-associated TMA is found in 2 forms: haemolytic uraemic syndrome (HUS) and thrombotic 
thrombocytopaenic purpura (TTP). It is typically a feature of chronic infection but can also be seen 
during acute retroviral syndrome. TMA is rare in comparison with HIVAN, however HIV-related TMA 
accounts for approximately 35% of TMA cases. It tends to occur more frequently in children and 
young males. HUS is characterized by microangiopathic anaemia and renal impairment, whereas TTP 
includes a pentad of microangiopathic anaemia, thrombocytopaenia, renal impairment, fever and 
neurological features. Nephrotic range proteinuria can be seen but is typically less than in HIVAN.27 
 
The pathogenesis of the disease is unknown. It is hypothesized to be due to endothelial cell injury 
and platelet deposition in the microvessels.27 Other factors include concomitant infections, 
deficiencies of inhibitors of platelet aggregation, cytotoxins and abnormalities of the coagulation 
cascade.  Heightened expression of tissue-type plasminogen activator and fibroblast growth factor 
are also thought to play a role. Deficiency in the ADAMTS13 (the protease that cleaves von 
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Willebrand factor) caused by autoimmune inhibitors or genetic mutations, has also been associated 
with TTP.48 Pathological findings in both forms are the deposition of platelets and fibrin rich thrombi 
in the glomerular capillaries and arterial microvasculature. Other features include fibrinoid necrosis, 
intimal oedema, onion-skin lesions and microcystic tubular lesions. The role of HIV-1 remains 
uncertain. The HIV-1 p-24 antigen has been found in endothelial cells within the spleen of a patient 
with TMA. The same antigen has also been seen in endothelial cells in the bone marrow and brain of 
HIV patients without TTP/HUS.27 
Prognosis of HIV patients with TMA is poor, with mortality rates of 66-100%.49 Treatment for TMA 
includes plasma infusion and plasmapheresis. Splenectomy is reserved for refractory cases. A South 
African study suggested that HIV patients respond better to fresh frozen plasma than HIV-negative 
patients and are less likely to require plasma exchange.50 Other therapies such as antiplatelet agents, 
glucocorticoids and immunoglobulin infusions have been used with variable success. There have 
been reports describing the beneficial effect of ARTs, but further investigation is needed.27 
1.5.3 Co-morbid Diseases  
Hypertension and diabetes mellitus are the leading causes of CKD in the general population. They 
account for 71% of ESRD cases and increase the risk of CKD 10-fold. These two chronic conditions are 
increasingly common in HIV patients. As mentioned before, in the Multicenter AIDS Cohort 
Study14% of patients had diabetes, 4-fold higher than in HIV negative patients. It was linked with 
cumulative exposure to nucleoside reverse-transcriptase inhibitors. Hypertension was 3 times 
commoner in study patients than in controls. Hypertension and diabetes was reported in 55% and 
20% respectively in a study of 129 HIV positive patients.16 This underlines the importance of 
optimizing blood pressure and attaining  glycaemic control so as to minimize the impact of CKD in 
HIV infected patients.51 Current recommendations for HIV positive individuals with nephropathy are 
that blood pressure should be controlled to no higher than 125/75 mmHg, with the initial use of 
ACE-Is or Angiotensin II receptor antagonists in those with proteinuria. Screening recommendations 
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suggest that if there is no sign of proteinuria initially, patients with an increased risk for the 
development of proteinuric kidney disease (including those with diabetes mellitus and hypertension) 
should undergo screening annually.33 
 
The risk of developing tuberculosis (TB) infection is 20-37 times higher in patients who are HIV 
positive. Of the 8.7 million new cases of TB diagnosed worldwide in 2011, 13% were HIV positive. 
The major burden of this falls in sub-Saharan Africa. 0.43 Million deaths worldwide were reported in 
patients with TB and HIV co-infection.52 Due to the high prevalence of co-infection, many patients 
with HIV-associated kidney disease will be co-infected with TB. There is a paucity of data related to 
TB and HIV-associated kidney disease, and the impact thereof. One study done in Western Kenya 
found that a history of tuberculosis was significantly associated with proteinuria.53 Acute kidney 
injury has been described as part of Immune reconstitution syndrome in TB patients who have been 
started on HAART. Histological examination of one such patient revealed severe granulomatous 
nephritis with interstitial infiltrates.54 Part of this study aims to determine the incidence and the 
impact of TB in our patients on outcomes.  
 
1.6 Treatment: outcome and complications 
1.6.1 Outcome of patients with HIV-associated kidney disease on HAART 
Studies show that although renal dysfunction in HIV patients starting HAART is a predictor of poor 
outcome, it does respond to ARTs.  A study done in Uganda of 508 ART-naive patients with renal 
insufficiency at baseline found that after 2 years of HAART, the median creatinine clearance 
increased significantly (53%).55 Another study showed patients with HIVAN on ARTs had better renal 
survival compared to those who did not receive treatment.38 As mentioned before, there are 
conflicting reports on HIV-associated kidney diseases other than HIVAN. This implies that earlier 
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diagnosis of kidney disease and additional therapeutical strategies need to be looked at in these 
patients to improve their outcome.15, 32 Interestingly, Fabian et al found that although there was 
clinical improvement with introduction of HAART, there was not a corresponding resolution of the 
histological lesions.32 
1.6.2 Current guidelines for HAART and complications of these drugs 
Most HAART regimens used in South Africa use a combination of two nucleoside reverse 
transcriptase inhibitors (NRTI) with one non-nucleoside reverse transcriptase inhibitor (NNRTI). With 
the introduction of numerous HIV therapies, the complications associated with HIV infection have 
expanded to include changes in metabolism secondary to drug usage. Documented side effects 
include peripheral insulin resistance, impaired glucose tolerance, lipodystrophy and bone 
demineralization related to possible mitochondrial dysfunction. In addition to direct nephrotoxicity, 
long-term use of antiretrovirals could advance the development of CKD through these metabolic 
complications.56 Tenofovir (TDF) has been included as part of the first line regimen in current 
guidelines, and is being used more commonly. Renal dysfunction was more frequent in a systematic 
review of 517 patients on TDF. They also found a greater risk of acute renal failure in those receiving 
TDF. However the clinical effect was small and should not restrict the use of TDF.57 A later 
observational analysis of 3316 patients initiated on ARTs showed severe impairment to be 
infrequent and differences between eGFRs with various ARTs (TDF, abacavir and nevirapine) to be 
small. Their findings suggest that in resource limited settings, routine monitoring of serum creatinine 
may not be mandatory and is unlikely to add benefit for the majority of patients.55 A study in 
Johannesburg found that the incidence of renal dysfunction related to tenofovir was most likely 
related to prior renal disease and dose adjustment was needed to improve outcomes.58 
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1.6.3 Dosing recommendations 
The NRTIs are primarily excreted by the kidneys; therefore reduced dosages are required for those 
with impaired renal function. Screening for kidney disease prior to initiation of ARTs is 
recommended by the HIV Medicine Association of the Infectious Diseases Society of America with 
subsequent dose modification for patients with  GFRs <60ml/min. Patients that have then been 
identified with CKD are recommended to have more frequent monitoring of kidney function, toxicity 
and therapeutic efficacy. Care should be taken not to allow for under-dosaging as this may lead to 
inadequate treatment and contribute to virological failure. The NRTIs are not tightly protein-bound 
and do not have a high molecular weight and therefore can be easily removed by dialysis. With the 
exception of abacavir, the NRTIs should generally be administered after dialysis. With the exception 
of nevirapine and indinavir, the NNRTIs, protease inhibitors (PIs) and fusion inhibitors are primarily 
excreted by the liver and do not need dose adjustment. These two should be administered after 
dialysis.33 
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Table 3 Dose adjustment of ART in Renal Disease 
Creatinine clearance/ GFR 
 
Drug 10 – 50ml/min <10ml/min 
AZT Unchanged 300 mg daily 
ddI >60 kg body weight: 
200 mg daily 
 
<60 kg body weight: 
150 mg daily 
>60 kg body weight: 
100 mg daily 
 
<60 kg body weight: 
75 mg daily 
3TC 150 mg daily 50 mg daily 
D4T 15 mg 12-hourly 15 mg daily 
ABC Unchanged Unchanged 
TDF AVOID AVOID 
PIs Unchanged Unchanged 
NNRTIs Unchanged Unchanged 
 
*Note: Adapted from Guidelines for antiretroviral therapy in adults. SAJHIVMED 2012, 13(3):124. 
Reproduced with kind permission from the Southern African HIV Clinicians Society.  
AZT = zidovudine; ddI = didanosine; 3TC = lamivudine; D4T = stavudine; ABC = abacavir; 
TDF = tenofovir; PI = protease inhibitor; NNRTI = non-nucleoside reverse transcriptase 
Inhibitor. 
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2. HYPOTHESIS AND AIMS  
 
2.1 Hypothesis 
Renal function in HIV positive patients with chronic kidney disease improves with introduction of 
ARTs.  
2.2 Aims and objectives 
This study aims to: 
1. Evaluate the outcomes of HIV positive patients with chronic kidney disease with the 
introduction of HAART over a minimum period of one year, using mortality and 
improvement in renal function and proteinuria over a one year period or longer. 
2. Evaluate the prevalence as well as the impact of common co-morbid conditions such as 
hypertension, diabetes mellitus, tuberculosis and malignancy on the outcomes of these 
patients. 
3. Examine predictors of outcome in patients with renal insufficiency who are started on 
HAART. 
 
 The main objectives of this study will be to: 
1. Assess the outcomes of HIV positive patients with background renal insufficiency to HAART, 
using mortality and improvement in renal function and proteinuria over a one year period or 
longer. 
2. Investigate the prevalence and impact of common co-morbid conditions such as 
hypertension, diabetes mellitus, tuberculosis and malignancy. 
3. Determine predictors (if any) of outcome.  
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3. METHODS 
 
3.1 Selection of patients 
A retrospective review was performed of 495 files of HIV positive patients attending the Charlotte 
Maxeke HIV Renal Clinic between 2006 and 2009. Ethics approval was received from the University 
of Witwatersrand Human Research Ethics Committee (Medical) – clearance number M10416. A total 
of 169 patients seen at the HIV Renal Clinic with CKD were included in the study. These patients 
were labelled as CKD using The National Kidney Foundation guidelines (kidney damage that persists 
for ≥ 3 months). 326 patients were excluded for a number of reasons: these patients were found to 
have AKI, were not initiated on ART, a minimum of 3 month follow up, results were not found, 
suffered from unrelated concomitant renal disease (e.g. lupus nephritis, polycystic kidney disease, 
urological complications), non HIV-related malignancies and renal transplant recipients. Histology 
results were available for 84 patients. These results were included, regardless of whether the 
patients were ultimately excluded from analysis of the response to ART. The study population was 
then divided into two groups. Group 1 (n=87) had baseline pre-ART initiation renal function results 
available. The second group (Group 2) (n=82) were on ART prior to being referred to the HIV Renal 
Clinic. Their underlying renal dysfunction may not have been detected at baseline or they developed 
renal dysfunction on ART. Results were collected at 3, 6, 12 and 24 months. 
3.2 Inclusion criteria 
- HIV positive  
- On ART 
- CKD (defined as kidney damage that persists for ≥ 3 months) 
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3.3 Exclusion criteria 
- AKI 
- Not on ART 
- Unrelated concomitant renal disease 
- Non HIV-related malignancies 
- Renal transplant recipients 
Demographic data such as age, gender and ethnicity and laboratory variables including serum 
haemoglobin, serum creatinine and urine protein were collected. Co-morbid conditions such as 
tuberculosis, hypertension, malignancy and diabetes mellitus were included as well. Kidney function 
was evaluated using serum creatinine and the MDRD formula and proteinuria. Proteinuria was 
estimated using urine dipsticks, spot protein: creatinine ratio and microalbumin: creatinine ratio. 
Renal dysfunction was defined as creatinine clearance ≤ 90µmol/l (calculated using the MDRD 
formula). Proteinuria was defined as ranging from microalbuminuria (microalbumin-to-creatinine 
ratio 3.4–33.9 mg/mmol) to overt proteinuria (protein-to-creatinine ratio > 0.03 g/mmol). Patients in 
both groups were on various regimens of ART and response was monitored using CD4 count and, 
where available, viral load. 
 
3.4 Statistical analysis  
Statistical analysis was performed using Stata Software version 8 and Graphpad InStat version 3. 
Demographics including gender, age and CD4 count were evaluated and compared to ensure there 
was no bias among groups. The differences in these were calculated using the ANOVA test. 
Comparison of renal function at different intervals was performed using the Kruskal-Wallis test. The 
associations of renal insufficiency with other factors were calculated using odds ratios with 95% 
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confidence intervals (CI). Further calculations of multivariable associations with 95% CIs were 
performed on the variables that were significant (p<0.1) on univariate analysis. Kaplan-Meier 
survival analysis was performed looking at 2 year survival post study dates.  
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4. RESULTS 
4.1 Demographic data 
As discussed previously, the participants were divided into 2 groups for analysis: those ART-naïve 
(Group 1) and those already on ART on presentation (Group 2). Table 4 describes the baseline data 
and Table 5 the outcome data at 12 and 24 months.  
Table 4 Baseline data 
  
 
Group 1 (ART naive) n = 87 
Group 2 (ART prior to 
presentation) n = 82 
      
Age Mean (±SD) 37.8 (±9.2) 41.2 (±11.3) 
Sex (% female) 42 42 
Race (% black) 100 96 
Hypertension (%) 37 (42) 34 (41) 
Diabetes (%) 11 (12) 11 (13) 
Tuberculosis (%) 28 (32) 25 (30) 
HIV-related Malignancies 5 (5) 2 (2) 
Serum creatinine µmol/l Median (IQR) 298 (144-667) 171 (119-349) 
eGFR (ml/minute/1.73m²) Median(IQR) 20.8 (9-50) 38.9 (20-69) 
CD4 count (cell/mm³) Median (IQR) 145 (74-273) 298 (191-371) 
Proteinuria (g/day) Median (IQR) 0.3 (0.13-0.78) 0.27 (0.08-0.64) 
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Table 5 Outcomes at 12 and 24 months 
  Group 1  Group 2   
       
Alive 34 30  
Died 18 15  
Lost to follow up 35 37  
Total  87 82  
      
GROUP 1     
  Month 0 Month 12 Month 24 
    
Patient number  82 53 43 
Median creatinine µmol/l (IQR) 298 (144-667) 162 (87-346) 137 (98.5-359) 
Median eGFR (ml/min per 1.73m²) (IQR) 20.8 (9.2-50) 52.4 (20.1-92.1) 57.7 (17.3-88.9) 
    
Patient number  60 35 18 
Median proteinuria (g/day) (IQR) 0.2 (0.13-0.78) 0.11 (0.05-0.53) 0.08 (0.05-0.22) 
      
GROUP 2     
  Month 0 Month 12 Month 24 
    
Patient number  82 53 47 
Median creatinine µmol/l (IQR) 172 (69-342) 154 (69-342) 137 (100-516) 
Median eGFR (ml/min per 1.73m²) (IQR) 38.9 (20-69) 46.2 (19-79) 47.3 (11.3-87) 
    
Patient number  42 27 16 
Median proteinuria (g/day) (IQR) 0.3 (0.08-0.6) 0.11 (0.03-0.36) 0.21 (0.08-0.4) 
 
Group 1 The mean age was 38 years, 42 (48%) were female, with a median baseline CD4 count of 
139 cell/mm³ (range 4-842cell/mm³). Hypertension was present in 37 patients (42%), Diabetes in 11 
(12%), Tuberculosis in 28 (32%) and HIV-related malignancies in 5 (5%).  The median baseline serum 
creatinine in this group was 298µmol/l (range 49-3294µmol/l) and the median baseline eGFR was 
20.8ml/min/1.73m² (range 1.7-167.6ml/min/1.73m²). The median serum creatinine at 12 months 
decreased to 162µmol/l (range 51-1566µmol/l; p<0.05) and 137µmol/l at 24 months (range 50-
1914µmol/l; p<0.05). The median eGFR at 12 months increased to 52.4 ml/min/1.73m² (range 3-
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203.9ml/min/1.73m²; p<0.05) and 57.7ml/min/1.73m² (range 2.2-167ml/min/1.73m²; p<0.05) at 24 
months respectively. The 3 and 6 month measurement differences were not statistically significant. 
Median baseline proteinuria was 0.3g/day (range 0.01-1.4g/day). The level of proteinuria at 12 
months was 0.11g/day (range 0.01-0.95g/day; p<0.05) and 0.08g/day at 24 months (range 0.02-
0.99g/day; p<0.05). Univariate analyses were performed to identify associations between poor renal 
outcomes and factors including hypertension, diabetes, tuberculosis, malignancy, baseline eGFR, 
baseline proteinuria level and haemoglobin. Those found to be significantly associated with a poor 
renal outcome were diabetes (OR 4.9, CI 1.2-18.9) (p 0.02) and baseline eGFR (OR 1.01, CI 1-1.03) (p 
0.01). On further multivariate analysis, these predictors continued to be significant: diabetes (OR 
4.24, CI 1.02-17.5) (p 0.04) and baseline eGFR (OR 1.01, CI 1-1.02) (p0.017). A total of 13 patients 
were receiving renal replacement therapy (RRT) prior to ART initiation, 8 haemodialysis and 5 
peritoneal dialysis. One patient was initiated on RRT during the study period and eventually went on 
to receive a kidney transplant in November 2011. 34 patients are still alive during the follow up 
period (2 year post study dates). 18 patients were known to have died, 3 of these were known to be 
from renal failure and 1 from complications of Hodgkin’s lymphoma. The others passed away at 
peripheral hospitals or the cause of death was unknown. 35 patients were lost to follow up.    
 
Group 2 The mean age for this group was 41 years, 35 (42%) were female, with a median baseline 
CD4 count of 298 cell/mm³ (range 2-1217cell/mm³). Hypertension was present in 34 patients (41%), 
diabetes in 11 (13%), tuberculosis in 25 (30%) and HIV-related malignancies in 2 (2%). The median 
time from initiation of ART to presentation to the HIV Renal Clinic was 25 months.  The median 
baseline serum creatinine in this group was 172µmol/l (range 54-1723µmol/l) and the median 
baseline eGFR 38.9ml/min/1.73m² (range 2.7-150.9ml/min/1.73m³). The median serum creatinine at 
12 months decreased to 154µmol/l (range 50-2082µmol/l) and 137µmol/l (range 61-1914µmol/l) at 
24 months. None of these however, were found to be statistically significant. The median eGFR at 12 
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months increased to 46.2 ml/min/1.73m² (range 2.9-151.1ml/min/1.73m²) and 47.3ml/min/1.73m² 
(range 2.5-140.9ml/min/1.73m²) at 24 months respectively. These were also found to be statistically 
insignificant (p=0.4256). Median baseline proteinuria was 0.3g/day (range 0.01-1.4g/day). The level 
of proteinuria at 12 months decreased to a median 0.11g/day (range 0.01-0.95g/day) and 
subsequently increased to 0.21g/day (range 0.02-0.99g/day) at 24 months. The overall change was 
statistically significant (p=0.0418). All factors analysed for association with a poor renal outcome in 
the univariate analysis were found to be statistically insignificant in this group. Therefore, further 
multivariate analysis was not performed. A total of 8 patients were receiving RRT prior to ART 
initiation, 5 haemodialysis and 3 peritoneal dialysis. 4 patients progressed to ESRD requiring RRT 
while on ART during the study period. 30 patients are still alive during the follow up period (2 years 
post study dates). 15 patients were known to have died, 5 of these were known to be from renal 
failure. The others passed away at peripheral hospitals or the cause of death was unknown. 37 
patients were lost to follow up.    
A comparison of the two groups in a Kaplan-Meier survival curve in Figure 2 below shows no 
statistically significant difference in patient survival between group 1 and group 2. 
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Figure 2 Kaplan-Meier survival estimates plot for overall survival of CKD patients stratified into 
Group 1 and 2. Analysis of data using the log-rank test showed no difference in survival between the 
two groups (p=0.7161)  
 
4.2 Renal histology 
A total of 84 patients had histological information available. 24 patients (20%) (9 in Group 1, 7 in 
Group 2 and 8 in the excluded group) had HIVAN as a primary diagnosis. 14 (11.6%) patients (8 in 
Group 1, 3 in Group 2 and 3 in the excluded group) had HIV-ICD. Other histological findings included 
chronic interstitial nephritis (CIN) (34) (28.4%), acute tubular necrosis (24) (20%), lupus nephritis (3), 
membranous glomerulopathy (2), membranoproliferative glomerulonephritis (2), IgA nephropathy 
(1), minimal change disease (1), crescentic glomerulopathy(2) , diabetic nephropathy (3), 
hypertensive nephrosclerosis (3), thrombotic microangiopathy (2), acute on chronic pyelonephritis 
(3), ischaemic necrosis secondary to analgesic nephropathy (1) and  immunotactoid glomerulopathy 
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(1). Patients in Group 1 and 2 were then analysed further. It was found that there were no significant 
differences in factors such as age, gender and CD4 count and so these two groups were combined 
for analysis. 
 
 
 
Figure 3 Renal histological patterns in HIV positive patients 
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HIVAN In this sub group, the changes in eGFR and urine PCR over the 24 month follow up period 
were found to be statistically insignificant, most likely due to the small sample size. There was 
however, an increase in the median eGFR from baseline of 26ml/min/1.73m² (range 3.2-
117.3ml/min/1.73m²) to 35ml/min/1.73m² (range 5.7-119.6ml/min/1.73m²; p=0.81) at 24 months.  
A decrease in urine PCR was also observed – 0.45g/day at baseline and 0.11 at 24 months; p=0.48.  
When the sub group was compared to the entire group (i.e. Group 1+Group2), it was found that 
there was no statistically significant difference in baseline, 12 or 24 month eGFR or urine PCR  
values. The histological diagnosis of HIVAN was not associated with a poor renal outcome on 
univariate analysis (OR 0.72).  
 
HIV-ICD In this group, the changes in eGFR and urine PCR over the 24 month period were also found 
to be statistically insignificant, most likely due to small sample size. Median eGFR increased from 
48ml/min/1.73m² to 92ml/min/1.73m² at 24 months. Median PCR at baseline was 0.45g/day and 
0.41g/day at 24 months. There was a significant difference in baseline eGFR in this sub group 
(48ml/min/1.73m²) compared to the entire group (27ml/min/1.73m²) (p=0.027). There was also a 
significant difference in eGFR at 12 months. The HIV-ICD group median eGFR was 103ml/min/1.73m² 
versus the whole study group (Groups 1+2) of 50ml/min/1.73m². There was no significant difference 
between the urine PCR of this group when compared with the entire group. The histological 
diagnosis of HIV-ICD was not associated with a poor renal outcome on univariate analysis (OR 0.34). 
 
Other The changes in eGFR and urine PCR over the duration of 24 months were not significant in this 
group. Median eGFR increased from 37ml/min/1.73m² at baseline to 56ml/min/1.73m² at 24 
months. Median PCR at baseline was 0.5g/day, decreasing to 0.13g/day at 24 months. The median 
eGFR of this group (37ml/min/1.73m²) was higher than 2that of Group 1 (27ml/min/1.73m²). 
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However, the differences in eGFR and PCR between the two groups over 24 months were not 
statistically significant. This histological group was not associated with a poor renal outcome on 
univariate analysis (OR 0.69). 
 
 
 
Figure 4 Kaplan-Meier survival estimates for renal survival of CKD patients stratified into two groups 
according to histology (HIVAN and HIV-ICD). Analysis of the data using the log-rank test showed no 
difference in survival between the two groups (p=0.761) 
 
A comparison of the two groups in a Kaplan-Meier survival curve in Figure 4 above shows no 
difference in renal survival between HIVAN and HIV-ICD.   
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5. DISCUSSION 
 
Most patients in Group 1 in this study (i.e. ART-naïve with pre-ART results available) presented with 
advanced HIV infection (with CD4 counts below 200) and advanced renal disease (CKD stage IV) with 
a median baseline serum creatinine of 298µmol/l (range 49-3294µmol/l) and median eGFR of 
20.8ml/min/1.73m² (range 1.7-167.6ml/min/1.73m²). There was a significant improvement in 
patients’ renal function by 12 months, which further improved at 24 months. Using the CKD staging 
system, renal function improved from stage IV to stage III at 12 months and remained stable at 24 
months. These findings are consistent with those found in Zambian5 and Ugandan⁵⁵ studies, where 
there was a significant improvement in renal function with the introduction of HAART. This 
improvement was also reflected in partial or complete resolution of proteinuria which remained 
stable. Other studies have had similar results with significant resolution of proteinuria with HAART.³², 
⁵⁹Low baseline eGFR was associated with poor renal outcome. This supports the need for early 
screening for renal disease, with baseline serum creatinine and proteinuria measurement in all HIV 
positive patients, and early treatment before fibrotic/sclerotic changes are established.43, 44 There 
may also be a need to further evaluate criteria for HAART eligibility. Current WHO guidelines include 
HIVAN as an AIDS-defining condition, but exclude other causes of renal dysfunction in HIV patients.³⁷ 
Renal dysfunction as detected by elevated serum creatinine could be looked at as an additional 
criterion for HAART initiation. Other non-invasive modalities could also be looked at to identify early 
renal disease. This takes on further significance in resource limited settings where modalities such as 
histological diagnosis may not be available.  
 
The prevalence of diabetes in our study was 12% and found to be associated with poor renal 
outcome (odds ratio 4.24, CI 1.02-17.5). These findings are similar to those of other studies such as 
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the Multicentre AIDS Cohort Study with a prevalence of 14% in HIV infected patients. Concomitant 
diabetes increases the risk of CKD 10-fold in HIV infected individuals. These findings point to the 
need for tight glycaemic control and more intensive monitoring in this group of patients in order to 
prevent the onset of CKD. Of note, concomitant tuberculosis had a relatively high prevalence of 32% 
but was not associated with poor renal outcome or increased mortality.     
 
Patients in Group 2 (i.e. those on HAART for a median of 25 months when referred to the HIV Renal 
Clinic with CKD) presented with less advanced renal disease (CKD stage III) and although there was 
an improvement in renal function, it was not statistically significant and there was no change in 
stage of CKD. There was a decrease in proteinuria at 12 months, but an increase once again at 24 
months. The significance of this change is unknown at this stage. Patients in this group were referred 
to the HIV Renal Clinic with pre-existing CKD. They may have developed this on HAART, or for many, 
it may have been missed on initial assessment as it is still fairly common that routine screening for 
renal disease is not done, even though guidelines recommend routine screening as standard of 
care.³³, ⁴³ It is also possible that those with more severe renal dysfunction may have demised prior to 
presentation to the HIV Renal Clinic. Since Group 2 presented at a median of 25 months after 
initiation of HAART, if we extrapolate from the results of both groups, it may suggest that renal 
function initially improves with the introduction of HAART and may stabilize by 12-24 months but 
will eventually start to deteriorate in the long term. A possible reason for this could be that this 
group of patients may had a high index of chronic damage (with sclerotic glomeruli and interstitial 
fibrosis) as they presented to the HIV renal clinic with evidence of persistent renal disease. There 
have been conflicting reports on this in other studies. Studies found that renal function worsened in 
patients with HIVAN and a high number of sclerotic glomeruli.⁴³, ⁴⁴ Fabian et al. found that despite a 
high chronicity index, patients’ renal function improved with HAART.³² These findings support early 
diagnosis of renal disease and initiation of treatment to prevent irreversible renal damage. There 
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were no factors found to be significantly associated with poor renal outcome in this group of 
patients.     
 
A study done by Bige et al found that the use of ACE-Is together with ART was associated with better 
renal outcomes. Our study had too few patients on ACE-Is on follow up for analysis.  
   
The most common histological diagnosis found in the 2 groups was HIVAN, followed by HIV-ICD. 
These findings are similar to other South African studies.¹⁰, ¹¹, ¹⁴ As has been mentioned before, there 
have been discrepant reports in studies examining the response of HIVAN to HAART. An American 
study³⁸ found that there is improvement in renal function with HAART, while another cohort study⁴⁴ 
reported progression to ESRD with HAART in those whose histology showed a high index of chronic 
damage. Our study showed an improvement in renal function in HIVAN patients with HAART 
(although not statistically significant) and was not associated with poor renal outcome on univariate 
analysis. Patients in the HIV-ICD group had a significantly higher baseline eGFR compared with the 
entire group, and renal function did in fact improve with the introduction of HAART. There have 
been discrepancies in studies evaluating patients with histological diagnoses other than HIVAN. An 
American study¹³ found no improvement in renal function with initiation of HAART while two South 
African studies¹⁴, ³² found an improvement in renal function. Of note, the level of proteinuria was 
similar in HIV-ICD and HIVAN, suggesting that the clinical profile of the two groups may be similar. 
This supports findings in other studies¹⁰, ¹¹, ¹³ that renal biopsy is still the gold standard in 
differentiating between the different entities in HIV renal disease. Neither histological diagnosis, 
however, was associated with a poor renal outcome. The third histological group included all other 
histological diagnoses. There was an improvement in eGFR in this group although it was not 
statistically significant, probably due to the small sample size. Of note, the largest proportion was 
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CIN with 41%. A South African study found that there was no resolution of the histological 
abnormalities in CIN with ARTs³². 
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6. STUDY LIMITATIONS 
There were a number of limitations in the study. Firstly, due to the retrospective nature of the study, 
some information (including kidney size to confirm CKD) and laboratory data were not available and 
patients were lost to follow up. Secondly, the MDRD formula was used, which may have 
overestimated the eGFR in our patients due to the generally lower muscle mass in this group of 
patients. The small numbers within the histological groups was another limitation and larger studies 
will be needed to confirm the results of this study. In addition, due to the relatively small number of 
patients on ACE-Is their impact on proteinuria and renal function could not be assessed.  
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7. CONCLUSION 
Our findings demonstrate that HIV patients with CKD respond well to HAART. This is reflected in 
improvement in eGFR and improvement in the level of proteinuria. Baseline low eGFR was 
associated with a poor renal outcome suggesting that initiation of HAART earlier in the course of the 
disease, before severe renal dysfunction has developed, improves renal outcomes and reduces the 
burden of HIV CKD. Patients who presented with persistent renal disease despite HAART were less 
likely to recover renal function, which also suggests implementing the recommendations for earlier 
diagnosis and treatment of renal disease in HIV patients. 
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